Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) was the target of some unusual options trading on Tuesday. Stock traders acquired 1,612 call options on the stock. This represents an increase of approximately 1,496% compared to the typical volume of 101 call options.
A number of equities analysts have recently commented on the company. Credit Suisse Group assumed coverage on Ironwood Pharmaceuticals in a report on Monday, November 27th. They issued a “buy” rating and a $19.00 target price for the company. ValuEngine cut Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 14th. Mizuho cut Ironwood Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $20.00 to $16.00 in a report on Wednesday, December 6th. BidaskClub cut Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Finally, Zacks Investment Research cut Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Four equities research analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $17.56.
Ironwood Pharmaceuticals (NASDAQ IRWD) opened at $15.12 on Friday. Ironwood Pharmaceuticals has a 1-year low of $13.43 and a 1-year high of $19.94. The company has a current ratio of 4.87, a quick ratio of 4.86 and a debt-to-equity ratio of -22.31. The stock has a market capitalization of $2,260.00, a price-to-earnings ratio of -15.75 and a beta of 1.45.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.07. Ironwood Pharmaceuticals had a negative return on equity of 645.22% and a negative net margin of 48.89%. The company had revenue of $86.80 million during the quarter, compared to analysts’ expectations of $73.59 million. During the same quarter in the previous year, the business earned ($0.18) EPS. Ironwood Pharmaceuticals’s revenue was up 31.3% compared to the same quarter last year. equities analysts expect that Ironwood Pharmaceuticals will post -1.12 earnings per share for the current year.
In other Ironwood Pharmaceuticals news, CEO Peter M. Hecht sold 113,405 shares of the firm’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $15.12, for a total transaction of $1,714,683.60. Following the completion of the transaction, the chief executive officer now owns 4,696,917 shares in the company, valued at approximately $71,017,385.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 115,769 shares of company stock valued at $1,752,491 in the last 90 days. 7.63% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in Ironwood Pharmaceuticals by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 10,761,867 shares of the biotechnology company’s stock valued at $203,184,000 after acquiring an additional 256,406 shares during the period. Janus Henderson Group PLC purchased a new position in Ironwood Pharmaceuticals during the 2nd quarter valued at $150,460,000. State Street Corp boosted its holdings in Ironwood Pharmaceuticals by 13.7% during the 2nd quarter. State Street Corp now owns 4,530,267 shares of the biotechnology company’s stock valued at $85,533,000 after acquiring an additional 545,464 shares during the period. EcoR1 Capital LLC boosted its holdings in Ironwood Pharmaceuticals by 29.2% during the 2nd quarter. EcoR1 Capital LLC now owns 3,753,635 shares of the biotechnology company’s stock valued at $70,869,000 after acquiring an additional 848,120 shares during the period. Finally, Pictet Asset Management Ltd. boosted its holdings in Ironwood Pharmaceuticals by 37.5% during the 3rd quarter. Pictet Asset Management Ltd. now owns 2,622,507 shares of the biotechnology company’s stock valued at $41,357,000 after acquiring an additional 715,147 shares during the period.
TRADEMARK VIOLATION WARNING: “Stock Traders Purchase High Volume of Ironwood Pharmaceuticals Call Options (IRWD)” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://ledgergazette.com/2018/01/14/stock-traders-purchase-high-volume-of-ironwood-pharmaceuticals-call-options-irwd.html.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.